Investigational drug · Phase 3
PTX-022
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Angiokeratomas, Pachyonychia Congenita.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "PTX-022"
First trial start
2022
Nov 15, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PTX-022", any sponsor or status.
Conditions studied
As listed on its trial records.
- Angiokeratomas
- Pachyonychia Congenita
Largest trials
Live from ClinicalTrials.gov: studies naming "PTX-022" as an intervention, largest first.
Palvella Therapeutics, Inc.Industry
NCT04893486 · 73 participants · Start May 6, 2021 · Primary completion Mar 13, 2023
Drug: PTX-022; Vehicle comparator · For: BCCs in Gorlin Syndrome Patients
Sites: Scottsdale, Arizona; Hot Springs, Arkansas; Palo Alto, California · 16 sites in all
- Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia CongenitaPivotal-lookingCompleted
Palvella Therapeutics, Inc.Industry
NCT03920228 · 73 participants · Start Apr 1, 2019 · Primary completion Sep 19, 2020
Drug: PTX-022; Placebo · For: Pachyonychia Congenita
Sites: Phoenix, Arizona; Palo Alto, California; New Haven, Connecticut · 9 sites in all
- A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia CongenitaPivotal-lookingRecruiting
Palvella Therapeutics, Inc.Industry
NCT05643872 · 45 participants (planned) · Start Nov 15, 2022 · Primary completion Oct 2023
Drug: PTX-022 · For: Pachyonychia Congenita
Sites: New Brighton, Minnesota
- VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia CongenitaPivotal-lookingCompleted
Palvella Therapeutics, Inc.Industry
NCT04520750 · 36 participants · Start Sep 1, 2020 · Primary completion Jun 30, 2021
Drug: PTX-022 · For: Pachyonychia Congenita
Sites: Phoenix, Arizona; Palo Alto, California; Fridley, Minnesota · 4 sites in all
- A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous MalformationsActive, not recruiting
Palvella Therapeutics, Inc.Industry
NCT06653842 · 15 participants (planned) · Start Dec 20, 2024 · Primary completion Nov 21, 2025
Drug: QTORIN 3.9% rapamycin anhydrous gel · For: Cutaneous Venous Malformations
Sites: Irvine, California; Palo Alto, California; Aurora, Colorado · 10 sites in all
Palvella Therapeutics, Inc.Industry
NCT07552077 · 15 participants (planned) · Start Apr 2026 · Primary completion Aug 2027
Drug: PTX-022 · For: Angiokeratomas
Sites: Sherman Oaks, California; Dawsonville, Georgia; Las Vegas, Nevada · 4 sites in all
Palvella Therapeutics, Inc.Industry
NCT05050149 · 12 participants · Start Jan 13, 2022 · Primary completion Nov 15, 2022
Drug: PTX-022 · For: Microcystic Lymphatic Malformation
Sites: Little Rock, Arkansas; Palo Alto, California; Fridley, Minnesota · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.